Akero Therapeutics Stock Price, News & Analysis

Akero Therapeutics (Nasdaq: AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 4, 2025, at 8:45 a.m. Pacific Time. Investors and interested parties can access the live webcast through Akero's investor relations website section at www.akerotx.com, with an archived replay available after the event.

Akero Therapeutics (NASDAQ: AKRO) reported significant Q1 2025 results, highlighted by groundbreaking Phase 2b SYMMETRY study outcomes showing statistically significant reversal of cirrhosis in MASH patients after 96 weeks of efruxifermin (EFX) treatment. Key findings include 39% of patients in the 50mg EFX group showing ≥1-stage fibrosis improvement, representing a 24% effect size over placebo. The company strengthened its financial position with a $402.5M follow-on offering, ending Q1 with $1.13B in cash reserves. Operating expenses increased to $80.9M, up from $60.0M in Q1 2024. The Phase 3 SYNCHRONY program continues to advance, with preliminary results from Real-World study expected in H1 2026. The SYMMETRY results were published in the New England Journal of Medicine and presented at EASL 2025, highlighting EFX's potential as a first- and best-in-class therapy for MASH treatment.

Akero Therapeutics (NASDAQ: AKRO) presented new analyses of their Phase 2b HARMONY trial for efruxifermin (EFX) in pre-cirrhotic MASH patients at EASL Congress 2025. The study utilized HistoIndex's AI-based qFibrosis® digital pathology analysis alongside conventional methods. Key findings showed that among patients treated with 50mg EFX, over 50% were classified as responders across all three endpoints (qFibrosis®, ELF test score, and FibroScan®), compared to less than 5% in the placebo group. At Week 96, the 50mg EFX group (N=26) showed similar response rates between conventional pathology (77%) and qFibrosis® (81%). Notably, qFibrosis® detected more responders at Week 24 (18 patients) compared to conventional pathology (10 patients), suggesting earlier detection of treatment response.

Akero Therapeutics (NASDAQ: AKRO) announced the publication of its Phase 2b SYMMETRY trial results in the New England Journal of Medicine, evaluating efruxifermin (EFX) for treating compensated cirrhosis due to MASH. The 96-week study showed significant fibrosis improvement, with 29% of participants in the EFX 50mg group and 21% in the 28mg group showing improvement compared to 11% in the placebo group.

At week 36, the primary endpoint of ≥1-stage fibrosis improvement without MASH worsening was achieved by 19% and 18% of participants in the 50mg and 28mg groups respectively, versus 13% for placebo. The treatment demonstrated improvements in liver injury markers, insulin sensitivity, and lipid metabolism. Safety profile was consistent with previous trials, with mainly mild to moderate gastrointestinal side effects.

Akero Therapeutics (NASDAQ: AKRO) presented 96-week results from its Phase 2b SYMMETRY trial of efruxifermin (EFX) at EASL Congress 2025. The trial evaluated EFX in patients with compensated cirrhosis caused by MASH. Key findings showed that 39% of patients treated with EFX 50mg demonstrated fibrosis improvement compared to 15% in the placebo group (p=0.009) among patients with baseline and week 96 biopsies. In the intent-to-treat population, 29% of EFX 50mg patients showed improvement versus 11% for placebo (p=0.031). The treatment effect more than doubled from Week 36 to Week 96, highlighting the importance of longer treatment duration. EFX demonstrated efficacy across patient subgroups, including those with type 2 diabetes and those on GLP-1 or statin medications. The safety profile remained consistent with previous trials, with mainly mild to moderate gastrointestinal side effects.

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotech company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming BofA Securities 2025 Healthcare Conference. The company's management will deliver a presentation on Tuesday, May 13, 2025, at 1:40 p.m. Pacific Time. Investors and interested parties can access the live webcast through Akero's investor relations website at www.akerotx.com, where an archived replay will also be available after the presentation.

Akero Therapeutics has announced multiple presentations at the upcoming EASL Congress 2025 in Amsterdam, showcasing research on their drug efruxifermin for treating metabolic diseases. The company will present two oral presentations and one poster focusing on liver disease treatment.

The first oral presentation by Dr. Mazen Noureddin will discuss efruxifermin's impact on fibrosis improvement in patients with compensated cirrhosis due to MASH, based on a 96-week Phase 2b trial (SYMMETRY). The second oral presentation by Prof. Quentin M. Anstee will explore the alignment of non-invasive fibrosis biomarkers with AI-based qFibrosis histology in MASH trials.

Additionally, a poster presentation by Prof. Jörn M. Schattenberg will demonstrate how qFibrosis enables earlier detection of fibrosis response in efruxifermin-treated patients with F2-F3 MASH in the 96-week HARMONY study. All presentations will take place between May 7-10, 2025.

Akero Therapeutics (NASDAQ: AKRO) reported significant progress in their Phase 2b SYMMETRY study, demonstrating unprecedented results in treating MASH (Metabolic dysfunction-Associated SteatoHepatitis). The study showed statistically significant reversal of compensated cirrhosis after 96 weeks of treatment with efruxifermin (EFX).

Key highlights include:

• 39% of patients in the 50mg EFX group showed ≥1 stage improvement in fibrosis
• 45% of non-GLP-1 patients experienced cirrhosis reversal
• 70% of patients treated with 50mg EFX showed ≥25% reduction in liver stiffness

The company completed enrollment for Phase 3 SYNCHRONY Real-World Study and expects preliminary results in H1 2026. Financial position remains strong with $797.8 million in cash and equivalents as of December 31, 2024, plus an additional $402.5 million raised in January 2025, providing runway into 2028.

Akero Therapeutics (NASDAQ: AKRO) has successfully closed its upsized public offering, raising approximately $402.5 million in gross proceeds. The offering consisted of two components: 6,427,170 shares of common stock priced at $48.00 per share (including the full exercise of underwriters' option for additional 1,093,750 shares), and 1,958,247 pre-funded warrants at $47.9999 per warrant with a $0.0001 exercise price.

The offering was managed by J.P. Morgan, Morgan Stanley, and Jefferies as joint book-running managers, with UBS Investment Bank acting as co-manager. The securities were offered through an automatically effective shelf registration statement previously filed with the SEC.